# Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

> **NCT02802228** · PHASE2 · COMPLETED · sponsor: **Cumberland Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Portal Hypertension
- Liver Cirrhosis

## Interventions

- **DRUG:** Ifetroban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02802228
- **Lead sponsor:** Cumberland Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-06
- **Primary completion:** 2018-07-17
- **Final completion:** 2018-07-17
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02802228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02802228, "Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02802228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*